GlassScriptPhysician profile
Avinash M Mondkar
NPI 1316956899
$8,271.33
in general payments reported to CMS, 2019-2025
40 companies · $778 in 2025
The $778 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,089 · 2020: $1,114 · 2021: $1,883 · 2022: $1,262 · 2023: $769 · 2024: $1,377 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,923.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,348.43 | 2019-2025 | |
| Pfizer INC. | $903.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $689.13 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $552.98 | 2019-2024 | Farxiga, Brilinta, Lokelma |
| Amgen INC. | $537.76 | 2019-2025 | Repatha, Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $536.48 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $431.91 | 2019-2025 | Trintellix |
| Novo Nordisk INC | $348.22 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amarin Pharma, INC. | $308.03 | 2020-2022 | |
| Kvk-Tech, INC. | $246.58 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $190.45 | 2021-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $188.67 | 2020-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $182.94 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Watchman Access System |
| Merck Sharp & Dohme LLC | $161.03 | 2019-2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $152.68 | 2021-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Mondkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.